The University of California, Davis (UCD) Cancer Clinical Trials Program represents a multidisciplinary team integrating the clinical and research expertise of physicians, pharmacologists, molecular biologists, biostatisticians, research nurses and clinical research coordinators for the NCI-designated UCD Cancer Center and its outreach network facilities, the Northern California VA Health Care System, and an extensive community affiliate program. As documented in this proposal, during the last grant cycle UCD continued to have a strong presence in both the science and patient accrual objectives of SWOG. During the grant cycle (January 2004 - December 2008), UCD and its affiliates led SWOG with 342 new patient registrations. Scientific input in SWOG is demonstrated by strong contributions to study design and coordination, as well as by positions of Group leadership and provision of special expertise and resources. Pilot studies at UCD and preclinical data generated by UCD investigators continue to be translated into SWOG trials. Even greater scientific input is anticipated during the next grant cycle due to key recruitments and continued growth of the UCD Cancer Center. The overall objective of this proposal is to improve cancer outcomes by providing protocol-governed interventions to the North-Central California population.
Specific aims are as follows: Provide a scientific resource to SWOG in correlative science, thereby facilitating translation of laboratory discoveries into hypothesis-driven clinical research. Provide clinical trials sophistication in the design and conduct of SWOG studies, emphasizing institutional strengths in Urologic Oncology and Lung Cancer. Improve access to NCI-sponsored clinical trials, including cancer control and prevention studies, to the community at large, emphasizing underserved rural and minority patient populations in our area. These goals will be addressed by a multidisciplinary team of investigators with considerable experience and expertise in the conduct of cancer clinical research, an already proven track record in SWOG, and the dedicated resources of UCD's NCI-designated Cancer Center. Thus, UCD is particularly well positioned to take full advaritage of new opportunities for facilitating and coordinating SWOG-related clinical research studies in North-Central California.

Public Health Relevance

Relevance of this UCD SWOG application to public health is demonstrated by the overall mission: to improve cancer outcomes, including cancer control, prevention and treatment, to the North-Central California population. Additionally, this proposal is designed to improve access to NCI-sponsored clinical trials to underserved rural and minority patient populations in our area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046441-25
Application #
8214703
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1993-01-01
Project End
2015-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
25
Fiscal Year
2012
Total Cost
$316,002
Indirect Cost
$110,472
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70

Showing the most recent 10 out of 105 publications